Log In or Create Account
CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Resources
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
Donate
FAQs
Menu
Phillip Chan, PhD, MBChB
Phillip Chan, PhD, MBChB
Associate Research Scientist
Yale University
New Haven, CT
CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Resources
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
Donate
FAQs
Practice Question of the Week
October 6, 2026: Drug-Drug Interactions With Antiretroviral Regimens
A 75-year-old person with HIV was no longer able to tolerate oral antiretroviral therapy and switched to lenacapavir (LEN) + cabotegravir (CAB) (intramuscular rilpivirine was not recommended due to the presence of nonnucleoside reverse transcriptase resistance mutations). Four weeks after the most recent injection, he had a cerebrovascular event. Clopidogrel was initiated by the neurologist. Which of the following best describes the risk of drug-drug interactions in this setting?
A. Both CAB and clopidogrel are UGT1A1 substrates, so levels of both agents may increase
B. LEN is a moderate CYP3A inducer and may increase plasma concentrations of clopidogrel
C. LEN is a moderate CYP3A inhibitor and may increase plasma concentrations of clopidogrel
D. Clopidogrel is a strong UGT1A1 inhibitor, and plasma levels of both LEN and CAB may increase
E. Drug interactions caused by LEN or CAB are only relevant around the maximum concentration (Cmax), which occurs 7 days after injection
Register for the Chicago Course
View Archived Questions
Leave Feedback
Subscribe
CLOSE
